BIOMARIN PHARMACEUTICAL INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $5.30 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2017-02-27
- BIOMARIN PHARMACEUTICAL INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $5.30M, a 91.15% decline from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $59.90M, a 11880.00% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $500.00K, a 78.26% decline from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $2.30M, a 283.33% increase from fiscal 2012.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2016-12-31 | $5.30M 10-K · filed 2017-02-27 | |
| 2015-12-31 | $59.90M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $500.00K 10-K · filed 2016-02-29 | -$500.00K 10-K · filed 2015-03-02 |
| 2013-12-31 | $2.30M 10-K · filed 2015-03-02 | |
| 2012-12-31 | $600.00K 10-K · filed 2014-02-26 | |
| 2011-12-31 | $1.80M 10-K · filed 2013-02-26 | |
| 2010-12-31 | -$264.40M 10-K · filed 2012-02-22 | |
| 2009-12-31 | -$26.70M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |